Ensign Peak Advisors Inc Buys 3,402 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Ensign Peak Advisors Inc grew its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 11.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,965 shares of the biotechnology company’s stock after acquiring an additional 3,402 shares during the period. Ensign Peak Advisors Inc’s holdings in Axon Enterprise were worth $19,592,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in Axon Enterprise by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company’s stock valued at $5,019,886,000 after purchasing an additional 275,959 shares during the period. Geode Capital Management LLC raised its stake in shares of Axon Enterprise by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company’s stock valued at $1,095,542,000 after buying an additional 65,097 shares during the period. Capital World Investors lifted its position in shares of Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock valued at $1,079,145,000 after buying an additional 841,772 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Axon Enterprise by 273.8% during the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock worth $659,128,000 after acquiring an additional 812,337 shares during the period. Finally, Norges Bank bought a new position in shares of Axon Enterprise during the 4th quarter worth $482,081,000. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $684.59 on Monday. Axon Enterprise, Inc. has a 1-year low of $273.52 and a 1-year high of $715.99. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $53.29 billion, a PE ratio of 176.90, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24. The firm’s 50 day simple moving average is $564.50 and its 200 day simple moving average is $585.83.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.07. The firm had revenue of $603.63 million for the quarter, compared to analysts’ expectations of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business’s quarterly revenue was up 31.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.15 earnings per share. As a group, analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Craig Hallum cut Axon Enterprise from a “buy” rating to a “cautious” rating in a research note on Monday, March 10th. Needham & Company LLC boosted their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a research report on Thursday. Barclays upped their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research note on Friday. Northcoast Research lowered shares of Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. Finally, The Goldman Sachs Group boosted their target price on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a report on Monday, January 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $640.91.

Insiders Place Their Bets

In related news, Director Jeri Williams sold 307 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the transaction, the director now directly owns 1,627 shares in the company, valued at approximately $899,275.44. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the sale, the chief executive officer now owns 3,063,982 shares in the company, valued at $1,657,583,622.18. The trade was a 0.33% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.